MedTrace Logo

Characterizing the Immune Response and Neuronal Damage in COVID-19

NCT04510012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2023-01-26

No results posted yet for this study

Summary

The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.

Conditions

Interventions

OTHER

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Sponsors & Collaborators

  • University of Bern

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Cédric Hirzel, MD · Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland

  • Leib L Stephen, MD · Institute for Infectious Diseases; Bern University

  • Jörg C Schefold, MD · Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-05
Primary Completion
2020-12-18
Completion
2021-01-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510012 on ClinicalTrials.gov